Cardinal Health, Inc. (CAH) Stock: Price, Forecast & Analyst Target
Cardinal Health, Inc. (CAH) — MoonshotScore 88/100 (Exceptional band), calculated Nov 18, 2026. Price $272.37 (-2.14%), as of the Nov 19, 2026 trading session; market cap $63.0B. Expected results Feb 4, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Cardinal Health, Inc. · CAH · NYSE · Healthcare · Medical - Distribution
Research dated 2026-09-12 (results through Q4 FY2026; Q1 FY2027 not covered): Cardinal Health moves pharmaceuticals and healthcare supplies through hospitals, pharmacies, clinical facilities, physician practices, and home-care channels, while also manufacturing selected medical products and operating specialized pharmaceutical services. The case depends on whether richer gross profit and dependable cash conversion can outweigh distribution-thin margins, pharmaceutical concentration, and debt that exceeds cash.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Cardinal Health (CAH)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A strong balance sheet and durable growth, at a cheap price, though quality is only decent; the market is already moving on it. Business Quality: Average; Financial Safety: Fortress; Valuation: Cheap; Growth Durability: Compounding; Momentum: Surging.
- quarterly revenue $67.51B (Q1 FY2027, quarter ended Sep 2026)
- EPS beat 8 of the last 8 reports
- expected results Feb 4, 2027
Helping: balance-sheet strength, an attractive price, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 91 | Exceptional | |
| 91 | Exceptional | |
| 91 | Exceptional | |
| 91 | Exceptional | |
| 88 | Exceptional | |
| 88 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $272.37 | |
| Change on the day | -2.14% | |
| 52-week range | $180.45–$286.29 | |
| Market capitalisation | $63.0B | — |
| Price / earnings (trailing) | 36.03 | |
| Shares traded on the day | 1.68M | |
| Beta (volatility vs the S&P 500) | 0.52 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Cardinal Health (CAH): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 17, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Cardinal Health (CAH), and what does it report?
Short answer · as of
Most revenue comes from distributing branded, generic, specialty, and consumer health products rather than inventing new medicines.
Research dated 2026-09-12 (results through Q4 FY2026; Q1 FY2027 not covered).
Cardinal Health also runs nuclear pharmacies, produces radiopharmaceuticals, repackages drugs, manages hospital pharmacies, and provides services for manufacturers, providers, and payers.
The Medical operation manufactures, sources, and distributes Cardinal Health-branded and national-brand supplies, devices, procedure kits, and laboratory products. Reported sales therefore include enormous volumes of pharmaceutical and medical product value passing through the network; the segment mix and narrow gross margin show why revenue is vast while the retained profit on each sales dollar is small.
What do the latest results show for Cardinal Health (CAH)?
Short answer · as of
The most recent reported quarter, Q1 FY2027, carried revenue of $67.51B.
Research dated 2026-09-12 (results through Q4 FY2026; Q1 FY2027 not covered).
The latest annual period delivered higher revenue and net income than the preceding annual period. In the latest quarter, revenue, gross profit, and operating profit advanced from the prior period, while net income edged lower; reported earnings have repeatedly exceeded estimates even though revenue has fallen short of consensus in the latest releases.
Management expects Pharmaceutical revenue to keep growing and points to expanding management-service platforms and distribution wins that began ramping recently. It is excluding a tariff-refund benefit from the comparison baseline because that benefit was nonrecurring, making underlying profit progression the more informative test.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $67.51B Nov 5, 2026
- Latest report · revenue estimate
- $66.67B Nov 5, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 5, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 5, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 5, 2026 | $67.51B | $66.67B | $3.2600 | $2.9400 |
| Aug 11, 2026 | $63.67B | $65.15B | $2.9100 | $2.4200 |
| Apr 30, 2026 | $60.94B | $62.10B | $3.1700 | $2.7900 |
| Feb 5, 2026 | $65.63B | $65.08B | $2.6300 | $2.3400 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 FY2027 | $67.51B | $554M | $2.38 (diluted) |
| Q4 FY2026 | $63.86B | $398M | $1.68 (diluted) |
| Q3 FY2026 | $60.94B | $399M | $1.69 (diluted) |
| Q2 FY2026 | $65.44B | $467M | $1.97 (diluted) |
What are the financial strengths and risks for Cardinal Health (CAH)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12 (results through Q4 FY2026; Q1 FY2027 not covered).
Operating cash flow has recovered sharply from earlier outflows and stayed positive through the recent run, with capital spending consuming only part of that inflow. Cash and short-term investments have also risen, but debt remains materially greater than cash, while short-term liquidity ratios sit below parity.
Cardinal Health earns a very narrow gross and operating margin on a pharmaceutical-heavy revenue base. A modest deterioration in the spread between product cost and selling price could therefore have an outsized effect on operating profit, even without a major change in sales volume; the favorable distress and accounting-quality screens do not remove that operating sensitivity.
What should you watch next at Cardinal Health (CAH)?
Short answer · as of
The next earnings report is expected on Feb 4, 2027.
Research dated 2026-09-12 (results through Q4 FY2026; Q1 FY2027 not covered).
At the scheduled earnings release, compare Pharmaceutical revenue direction with management's growth expectation and look for evidence that the expanding management-service platforms and recently ramped distribution wins are contributing to gross profit, not merely sales. Recent earnings beats alongside revenue misses make gross-profit and operating-profit progression more revealing than the top line alone.
Cash conversion deserves the same attention: sustained operating inflow after capital spending would reinforce the recent recovery, while renewed working-capital outflows would weaken it. Longer-range estimates assume continued expansion in revenue and earnings, so any break in that pattern would change the expectations surrounding the business.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does Cardinal Health compare with its peers?
Short answer
Cardinal Health's score ranks 5th of 10 in the bounded comparison shown, against 9 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12 (results through Q4 FY2026; Q1 FY2027 not covered).
Cardinal Health is more than a pharmaceutical wholesaler. Its nuclear pharmacies, radiopharmaceutical production, specialty services, hospital pharmacy management, branded medical products, and procedure kits create service and manufacturing exposure that a pure distributor would not have.
Nor does it resemble a drug developer or a pure medical-device manufacturer: pharmaceutical distribution remains overwhelmingly dominant in the reported revenue mix, and the consolidated economics retain the high-sales, thin-margin character of distribution. The distinctive structure is a pharmaceutical logistics engine paired with smaller specialized-service and medical-product operations.
| Company | Price | Market value | Score |
|---|---|---|---|
| $942.04 Nov 19, 2026 | $59.2B | 96 5-pillar Nov 18, 2026 | |
| $46.66 Nov 19, 2026 | $2.96B | 96 5-pillar Nov 18, 2026 | |
| $105.23 Nov 18, 2026 | $60.5B | 93 5-pillar Nov 18, 2026 | |
| $1084.43 Nov 18, 2026 | $125B | 92 5-pillar Nov 18, 2026 | |
| Cardinal Health (CAH) — this page | $272.37 | $63.0B | 88 |
| $341.25 Nov 19, 2026 | $65.1B | 86 5-pillar Nov 18, 2026 | |
| $9.08 Nov 18, 2026 | $39.8B | 75 5-pillar Nov 18, 2026 | |
| $85.69 Nov 18, 2026 | $9.47B | 73 5-pillar Nov 18, 2026 | |
| $212.73 Nov 19, 2026 | $57.9B | 68 5-pillar Nov 18, 2026 | |
| $50.62 Nov 18, 2026 | $2.40B | 63 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $265.00 – $321.00
- Consensus target
- $288.27
- Median target
- $290.00
Consensus record · Captured .
Measured against a quoted price of $272.37 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Nov 12, 2026
- Transactions
- 65
- Identified insiders
- 18
- Purchases
- 0
- Sales
- 31
- Other transactions
- 34
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held CAH in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.12% | $28.57M | Trimmed −2.8% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Common Questions About CAH (Healthcare)
Research dated 2026-09-12 (results through Q4 FY2026; Q1 FY2027 not covered); the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why does Cardinal Health generate so much revenue with such a thin margin?
Pharmaceutical distribution dominates the revenue mix, so the value of medicines flowing through Cardinal Health is recorded as sales while the company retains only a narrow spread. That creates enormous reported revenue without manufacturer-like margins.
What do Cardinal Health nuclear pharmacies add to the Pharmaceutical business?
They extend the business beyond conventional drug delivery into nuclear-pharmacy management and radiopharmaceutical production. Those specialized capabilities sit alongside repackaging, specialty support, and pharmacy-management services.
Why is Cardinal Health removing the tariff refund from its earnings baseline?
Management described the refund benefit as nonrecurring and excludes it to make future periods comparable with the underlying business. Operational progress therefore needs to stand without that benefit.
How important are Cardinal Health medical products beside pharmaceutical distribution?
Pharmaceutical activity is far larger in the reported revenue mix, but the Medical operation adds branded manufacturing, sourcing, procedure kits, and supply-chain relationships across hospitals, surgical centers, and laboratories. It broadens what Cardinal Health supplies without changing the company's distribution-led economics.
What is the CAH stock price today?
The last price recorded for Cardinal Health, Inc. (CAH), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the CAH price target?
The analyst consensus price target for Cardinal Health, Inc. (CAH), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 42 figures on this page — 1 from SEC filings and earnings calls, 35 from Financial Modeling Prep (FMP), 3 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold CAH
Funds in our ETF coverage that list CAH among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| SMI 3Fourteen Full-Cycle Trend ETF (FCTE) | 5.30% | |
| Liberty One Tactical Income ETF (LOTI) | 2.85% | |
| JMID ETF | 2.59% | |
| SPCT ETF | 2.56% |